{
    "name": "disulfiram",
    "comment": "Rx",
    "other_names": [
        "Antabuse"
    ],
    "classes": [
        "Psychiatry Agents",
        "Other"
    ],
    "source": "https://reference.medscape.com/drug/disulfiram-343199",
    "pregnancy": {
        "common": [
            "Pregnancy Category: C",
            "Lactation: excretion in milk unknown/not recommended"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: excretion in milk unknown/not recommended"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [
                "Never administer to a patient in a state of alcohol intoxication or without patient's full knowledge",
                "Instruct patient's relatives accordingly"
            ],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Ethanol, metronidazole, paraldehyde, any alcohol-containing products (e.g., some mouthwashes)",
                "Severe cardiac disease",
                "Coronary occlusion",
                "Psychosis",
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "When EtOH ingested by patient taking disulfiram: flushing, throbbing HA, N/V, diaphoresis, thirst, SOB, syncope, vertigo, blurred vision, confusion; respiratory depression, cardiac arrhythmias, MI or liver failure may occur",
                "Use caution in diabetes, hypothyroidism, seizures, nephritis, hepatic impairment",
                "Severe hepatitis and/or hepatic failure has been associated with therapy even in patients without prior history of abnormal hepatic function"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "benznidazole",
            "description": {
                "common": "benznidazole, disulfiram.\nEither increases toxicity of the other by aldehyde dehydrogenase inhibition. Contraindicated. Psychotic reactions have been reported in patients who were coadministered disulfiram and nitroimidazole agents (structurally related to benznidazole). Do not prescribe benznidazole to patients who have taken disulfiram within the last 2 weeks."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dronabinol",
            "description": {
                "common": "disulfiram increases toxicity of dronabinol by aldehyde dehydrogenase inhibition. Contraindicated. Dronabinol oral solution (Syndros) contains 50% (w/w) dehydrated alcohol 5.5% (w/w) propylene glycol, which can produce disulfiramlike reactions if coadministered. Discontinue disulfiram at least 14 days before starting dronabinol solution and do not administer disulfiram within 7 days of completing treatment with dronabinol solution."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eliglustat",
            "description": {
                "common": "disulfiram increases levels of eliglustat by affecting hepatic enzyme CYP2D6 metabolism. Contraindicated. If coadministered with strong or moderate CYP2D6 inhibitors, reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive  and intermediate metabolizers;  eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ritonavir",
            "description": {
                "common": "disulfiram increases toxicity of ritonavir by aldehyde dehydrogenase inhibition. Contraindicated. Interaction only associated with oral solution, which contains 42% alcohol."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine, disulfiram.\nEither increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ethanol",
            "description": {
                "common": "disulfiram will increase the level or effect of ethanol by  affecting hepatic enzyme CYP2E1 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "disulfiram will increase the level or effect of lonafarnib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of lonafarnib (a sensitive CYP3A substrate) with weak CYP3A inhibitors is unavoidable, reduce to, or continue lonafarnib at starting dose. Closely monitor for arrhythmias and events (eg, syncope, heart palpitations) since lonafarnib effect on QT interval is unknown."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metronidazole",
            "description": {
                "common": "disulfiram increases toxicity of metronidazole by decreasing metabolism. Contraindicated. Enhanced CNS & cardiac toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "disulfiram and pexidartinib both increase  Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selinexor",
            "description": {
                "common": "selinexor, disulfiram. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tinidazole",
            "description": {
                "common": "tinidazole increases toxicity of disulfiram by aldehyde dehydrogenase inhibition. Avoid or Use Alternate Drug. Alcoholic beverages and preparations containing ethanol or propylene glycol should be avoided during tinidazole therapy and for 3 days afterward because abdominal cramps, nausea, vomiting, headaches, and flushing may occur. Tinidazole should not be given to patients who have taken disulfiram within the last two weeks. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tipranavir",
            "description": {
                "common": "disulfiram, tipranavir. Mechanism: decreasing metabolism. Avoid or Use Alternate Drug. Risk of disulfiram reaction (tipranavir capsules contain alcohol)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alprazolam",
            "description": {
                "common": "disulfiram increases levels of alprazolam by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "disulfiram will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "avapritinib",
            "description": {
                "common": "disulfiram will increase the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "axitinib",
            "description": {
                "common": "disulfiram increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "disulfiram will increase the level or effect of brexpiprazole by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Administer a quarter of brexpiprazole dose if coadministered with a moderate CYP2D6 inhibitor PLUS a strong/moderate CYP3A4 inhibitor. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cholic acid",
            "description": {
                "common": "disulfiram increases toxicity of cholic acid by decreasing elimination. Modify Therapy/Monitor Closely. Avoid concomitant use of inhibitors of the bile salt efflux pump (BSEP). May exacerbate accumulation of conjugated bile salts in the liver and result in clinical symptoms. If concomitant use is necessary, monitor serum transaminases and bilirubin."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonazepam",
            "description": {
                "common": "disulfiram increases levels of clonazepam by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clorazepate",
            "description": {
                "common": "disulfiram increases levels of clorazepate by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cocaine topical",
            "description": {
                "common": "disulfiram increases levels of cocaine topical by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam",
            "description": {
                "common": "disulfiram increases levels of diazepam by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethotoin",
            "description": {
                "common": "disulfiram will increase the level or effect of ethotoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "disulfiram will increase the level or effect of etravirine by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "finerenone",
            "description": {
                "common": "disulfiram will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor serum potassium during initiation and dosage adjustment of either finererone or weak CYP3A4 inhibitors. Adjust finererone dosage as needed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flibanserin",
            "description": {
                "common": "disulfiram will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased flibanserin adverse effects may occur if coadministered with multiple weak CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "disulfiram will increase the level or effect of fosphenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "green tea",
            "description": {
                "common": "disulfiram increases levels of green tea by decreasing elimination. Use Caution/Monitor. Combination may increase caffeine levels. Caution should be taken due to increased risk of adverse effects due to caffeine in green tea."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "disulfiram will increase the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "disulfiram will increase the level or effect of isoniazid by  affecting hepatic enzyme CYP2E1 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "disulfiram increases levels of ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor when coadministered with weak CYP3A4 inhibitors ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lemborexant",
            "description": {
                "common": "disulfiram will increase the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Lower nightly dose of lemborexant recommended if coadministered with weak CYP3A4 inhibitors. See drug monograph for specific dosage modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lomitapide",
            "description": {
                "common": "disulfiram increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lomitapide dose should not exceed 30 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "disulfiram will increase the level or effect of midazolam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.  Coadministration of mild CYP3A4 inhibitors with midazolam intranasal may cause higher midazolam systemic exposure, which may prolong sedation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "disulfiram will increase the level or effect of oliceridine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "phenytoin",
            "description": {
                "common": "disulfiram will increase the level or effect of phenytoin by  affecting hepatic enzyme CYP2C9/10 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "procarbazine",
            "description": {
                "common": "disulfiram, procarbazine. Mechanism: unknown. Use Caution/Monitor. Risk of delirium (case report)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tamsulosin",
            "description": {
                "common": "disulfiram increases levels of tamsulosin by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "disulfiram will increase the level or effect of tazemetostat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tranylcypromine",
            "description": {
                "common": "disulfiram, tranylcypromine. Mechanism: unknown. Use Caution/Monitor. Possible CNS delirium including agitation, visual hallucinations, and disorientation may occur. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triazolam",
            "description": {
                "common": "disulfiram increases levels of triazolam by decreasing metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetaminophen",
            "description": {
                "common": "disulfiram will increase the level or effect of acetaminophen by  affecting hepatic enzyme CYP2E1 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetaminophen IV",
            "description": {
                "common": "disulfiram will increase the level or effect of acetaminophen IV by  affecting hepatic enzyme CYP2E1 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetaminophen rectal",
            "description": {
                "common": "disulfiram will increase the level or effect of acetaminophen rectal by  affecting hepatic enzyme CYP2E1 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alosetron",
            "description": {
                "common": "disulfiram will increase the level or effect of alosetron by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bosentan",
            "description": {
                "common": "disulfiram will increase the level or effect of bosentan by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "celecoxib",
            "description": {
                "common": "disulfiram will increase the level or effect of celecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "chlordiazepoxide",
            "description": {
                "common": "disulfiram increases levels of chlordiazepoxide by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dapsone",
            "description": {
                "common": "disulfiram will increase the level or effect of dapsone by  affecting hepatic enzyme CYP2E1 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "diclofenac",
            "description": {
                "common": "disulfiram will increase the level or effect of diclofenac by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ethotoin",
            "description": {
                "common": "disulfiram increases levels of ethotoin by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "flurbiprofen",
            "description": {
                "common": "disulfiram will increase the level or effect of flurbiprofen by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "disulfiram will increase the level or effect of fluvastatin by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "disulfiram increases levels of fosphenytoin by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ibuprofen",
            "description": {
                "common": "disulfiram will increase the level or effect of ibuprofen by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ibuprofen IV",
            "description": {
                "common": "disulfiram will increase the level or effect of ibuprofen IV by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isocarboxazid",
            "description": {
                "common": "disulfiram, isocarboxazid. Mechanism: unknown. Minor/Significance Unknown. Risk of delirium (case report)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "linezolid",
            "description": {
                "common": "disulfiram, linezolid. Mechanism: unknown. Minor/Significance Unknown. Risk of delirium (case report)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "meloxicam",
            "description": {
                "common": "disulfiram will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metronidazole topical",
            "description": {
                "common": "disulfiram increases toxicity of metronidazole topical by decreasing metabolism. Minor/Significance Unknown. Enhanced CNS & cardiac toxicity with oral metronidazole and disulfiram; less likely to occur with topical administration because of low absorption."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "metronidazole vaginal",
            "description": {
                "common": "disulfiram increases toxicity of metronidazole vaginal by decreasing metabolism. Minor/Significance Unknown. Enhanced CNS & cardiac toxicity with oral metronidazole and disulfiram; less likely to occur with vaginal administration because of low absorption."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenelzine",
            "description": {
                "common": "disulfiram, phenelzine. Mechanism: unknown. Minor/Significance Unknown. Risk of delirium (case report)."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "phenytoin",
            "description": {
                "common": "disulfiram increases levels of phenytoin by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "piroxicam",
            "description": {
                "common": "disulfiram will increase the level or effect of piroxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ramelteon",
            "description": {
                "common": "disulfiram will increase the level or effect of ramelteon by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "disulfiram will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "disulfiram will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sevoflurane",
            "description": {
                "common": "disulfiram will increase the level or effect of sevoflurane by  affecting hepatic enzyme CYP2E1 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sulfamethoxazole",
            "description": {
                "common": "disulfiram will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "theophylline",
            "description": {
                "common": "disulfiram increases levels of theophylline by decreasing metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "disulfiram will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "voriconazole",
            "description": {
                "common": "disulfiram will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Headache",
            "percent": null
        },
        {
            "name": "Impotence",
            "percent": null
        },
        {
            "name": "Metallic aftertaste",
            "percent": null
        },
        {
            "name": "Acneiform eruptions",
            "percent": null
        },
        {
            "name": "Polyneuritis",
            "percent": null
        },
        {
            "name": "Rash",
            "percent": null
        },
        {
            "name": "Hepatitis",
            "percent": null
        },
        {
            "name": "Peripheral neuropathy",
            "percent": null
        },
        {
            "name": "Optic neuritis",
            "percent": null
        },
        {
            "name": "Psychotic disorder",
            "percent": null
        }
    ]
}